Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of methadone in a sample of Iranian (Mazandarani) opiate users undergoing methadone maintenance treatment

authors:

avatar Mohammad-Reza Shiran 1 , * , avatar Hosseinzadeh Rasa 1 , avatar Abolhassan Hamidikenari 1 , avatar Mehran Zarghami 1 , avatar Nargess Lamsehchi 1 , avatar Mohammad-Reza Rafati 2

Psychiatry and Behavioral Sciences Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
Department of Pharmacotherapy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
Iranian Journal of Psychiatry and Behavioral Sciences: Vol.5, issue 2; 53-61
published online: December 31, 2011
article type: Original Article
received: April 20, 2011
revised: July 20, 2011
accepted: July 04, 2011

How To Cite Shiran M, Rasa H, Hamidikenari A, Zarghami M, Lamsehchi N, et al. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of methadone in a sample of Iranian (Mazandarani) opiate users undergoing methadone maintenance treatment. Iran J Psychiatry Behav Sci. 2011;5(2): 53-61. 

Abstract

Objective: To investigate the pharmacokinetics (PK) and PK- pharmacodynamic (PD) relationship of methadone in a cohort of outpatients undergoing methadone maintenance treatment (MMT).
Methods: Sixty male patients undergoing MMT with a mean ±SD methadone daily dosage of 58 ± 34 mg were enrolled in this study. A 5-ml blood sample was collected before the daily intake of methadone. As a PD measure, the Subjective Opioid Withdrawal Scale (SOWS) form was completed immediately after obtaining the blood sample. Blood samples were taken and the forms were completed 4-5 times more (up to 24 hr) after the daily intake of methadone. Plasma methadone was analyzed using HPLC. Population PK/PD analysis was performed using population pharmacokinetics modeling software P-Pharm.
Results: Significant decreases (p< 0.05) were observed in the SOWS scores during 10 hours after methadone intake. The SOWS had returned to baseline by 24 hr after using methaodone (p= 0.98). A considerable interindividual variability in the CL/F (16 fold), EC50 (3 fold) and Emax (6 fold) for methadone was observed.
Conclusion: Withdrawal symptoms were significantly improved in MMT patients after taking methadone and the PD measure was substantially affected by fluctuations in plasma methadone concentration. However, The SOWS had returned to baseline by 24 hr after using mathadone. Thus, a once daily dosing of methadone may not be suitable for those MMT patients who experience a significant withdrawal disturbance in the latter part of the interdose interval. This may increase the perceived severity of withdrawal and induce a craving for additional opioids.
Declaration of Interest: None.
Citation: Shiran MR, Hosseinzadeh R, Hamidikenari A, Zarghami M, Lamsehchi N, Rafati MR. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of methadone in a sample of Iranian (Mazandarani) opiate users undergoing methadone maintenance treatment. Iran J Psychiatry Behav Sci 2011; 5(2): 53-61.

Fulltext

Full text is available in the PDF.

References

  • 1.

    References are available in the PDF.

Scarlet Cullen
2020-02-07 10:57:04
“International Expertise Gathering in the Area of Pharmaceutical Sciences Conference” Conference Series cordially invites participants from all over the world to attend “20th Annual Meet on Pharmaceutical Sciences”, scheduled during May 10-11,2020 at Yokohama, Japan, and focused on the theme “Exploring the innovations leading to change the Pharmacy’’. The conference is a specially organized two days event which will provide a multi-channel communication platform that brings together both “producers” and “consumers” of pharma world of generic sector. It includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. It is a perfect platform for researchers, scientists and, delegates to share experience, Poster collaborations across industry and academia, and evaluate emerging technologies across the globe. Conference Series llc LTD organizes a conference series of 1000+ Global Events inclusive of 1000+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members. Website: https://drugs.pharmaceuticalconferences.com/ https://drugs.pharmaceuticalconferences.com/abstract-submission.php https://drugs.pharmaceuticalconferences.com/registration.php

reply